Is Tremfya approved for psoriatic arthritis?
Yes, Tremfya (guselkumab) is FDA-approved for active psoriatic arthritis (PsA) in adults.[1] The agency granted approval in 2020 based on Phase 3 trials (DISCOVER-1 and DISCOVER-2) showing it reduced joint pain, swelling, skin symptoms, and physical function limitations compared to placebo.[1][2]
How does Tremfya work for PsA?
Tremfya targets interleukin-23 (IL-23), a cytokine driving inflammation in PsA. Patients receive 100 mg subcutaneous injections at week 0, week 4, then every 8 weeks. In trials, 50-70% achieved ACR20 response (20% improvement in American College of Rheumatology criteria) by week 24.[2]
What do real-world results show?
Post-approval studies confirm efficacy: A 2023 analysis found 60% of PsA patients reached minimal disease activity after one year, with sustained skin clearance in those with psoriasis overlap.[3] It matches or exceeds TNF inhibitors for joint and skin control in head-to-head data.
Who qualifies and what are common side effects?
Approved for adults with active PsA, alone or with methotrexate. Not for children under 18. Upper respiratory infections (15-20%), headaches, and injection-site reactions occur most often; serious risks include infections and rare hypersensitivity.[1][4] Screen for tuberculosis before starting.
How does Tremfya compare to other PsA treatments?
| Treatment | Mechanism | Dosing | ACR20 Response Rate (Week 24) | Key Edge |
|-----------|-----------|--------|-------------------------------|----------|
| Tremfya | IL-23 inhibitor | Every 8 weeks | 50-70%[2] | Strong skin/joint dual control |
| Cosentyx (secukinumab) | IL-17 inhibitor | Every 4 weeks | 50-60%[5] | Faster skin clearance |
| Enbrel (etanercept) | TNF inhibitor | Weekly | 40-50%[6] | Cheaper generics available |
| Xeljanz (tofacitinib) | JAK inhibitor | Daily oral | 60-65%[7] | Pill option, no injections |
Tremfya stands out for less frequent dosing and psoriasis-heavy PsA.
When does Tremfya's patent expire?
Core patents on guselkumab expire around 2032-2033 in the US, with formulation patents extending to 2034.[8] No biosimilars approved yet; challenges from Amgen and Samsung Bioepis are ongoing.
Cost and access details
List price is about $6,500 per dose (every 8 weeks), or $40,000-$50,000 annually without aid.[9] Janssen offers copay cards capping out-of-pocket at $5/month for eligible insured patients.
[1]: FDA Label for Tremfya
[2]: New England Journal of Medicine - DISCOVER Trials
[3]: Rheumatology - Real-World Guselkumab Study
[4]: Tremfya Safety Profile
[5]: Cosentyx PsA Data
[6]: Enbrel Pivotal Trial
[7]: Xeljanz PsA Approval
[8]: DrugPatentWatch - Tremfya Patents
[9]: GoodRx - Tremfya Pricing